Compare Dell Technologies Inc (DELL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Dell Technologies (DELL) trades at $574.74, down 0.73% on the day, with a bullish technical signal and strong fundamental momentum. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $7.04 surpassing expectations by 43%. The company's AI server business is a key growth driver, with a backlog surging to $95 billion and fiscal 2027 revenue guidance raised to approximately $192 billion. Positive analyst sentiment is reflected in a 55.56% buy rating, though the stock trades above the consensus price target of $566.35.

The outlook for Dell is optimistic, driven by explosive AI server demand and robust financial performance. Investment opportunities include continued revenue growth and margin expansion, supported by a capital-light model. Risks include execution challenges in meeting high demand, competitive pressures, and market volatility. The stock's current valuation at a P/E of 33.42 may limit near-term upside if growth moderates.

IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.

Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.